US20030064525A1 - Meter - Google Patents

Meter Download PDF

Info

Publication number
US20030064525A1
US20030064525A1 US10264890 US26489002A US2003064525A1 US 20030064525 A1 US20030064525 A1 US 20030064525A1 US 10264890 US10264890 US 10264890 US 26489002 A US26489002 A US 26489002A US 2003064525 A1 US2003064525 A1 US 2003064525A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
terminals
instrument
signal
cell
applying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10264890
Other versions
US20040005716A9 (en )
Inventor
Martin Liess
Original Assignee
Liess Martin Dieter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes electrical and mechanical details of in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration

Abstract

An apparatus (31, 32, 132) and method for determining the concentration of a medically significant component (for example, glucose) of a biological fluid (for example, blood) comprise providing a cell (31) for receiving a sample of the fluid (for example, blood). The cell (31) supports a chemistry which reacts with the medically significant component (for example, glucose), and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. An instrument (32, 132) has first (34-2, 134-2) and second (34-3, 134-3) terminals complementary to the first and second terminals, respectively, of the cell (31). An assessment controller (52, 54, 148, 158) is provided. The apparatus determines the type of sample and the concentration of a medically significant component of the sample.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to methods and apparatus for improving the accuracy of measurements made with instruments of the type described in, for example, U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and 5,508,171. The invention is disclosed in the context of such an instrument, but is believed to be useful in other instruments of this general-type as well. [0001]
  • There are a number of instruments for the determination of the concentrations of biologically significant components of bodily fluids, such as, for example, the glucose concentration of blood. There are, for example, the instruments described in U.S. Pat. Nos. 3,770,607; 3,838,033; 3,902,970; 3,925,183; 3,937,615; 4,005,002; 4,040,908; 4,086,631; 4,123,701; 4,127,448; 4,214,968; 4,217,196; 4,224,125; 4,225,410; 4,230,537; 4,260,680; 4,263,343; 4,265,250; 4,273,134; 4,301,412; 4,303,887; 4,366,033; 4,407,959; 4,413,628; 4,420,564; 4,431,004; 4,436,094; 4,440,175; 4,477,314; 4,477,575; 4,499,423; 4,517,291; 4,654,197; 4,671,288; 4,679,562; 4,682,602; 4,703,756; 4,711,245; 4,734,184; 4,750,496; 4,759,828; 4,789,804; 4,795,542; 4,805,624; 4,816,224; 4,820,399; 4,897,162; 4,897,173; 4,919,770; 4,927,516; 4,935,106; 4,938,860; 4,940,945; 4,970,145; 4,975,647; 4,999,582; 4,999,632; 5,108,564; 5,128,015; 5,243,516; 5,269,891; 5,288,636; 5,312,762; 5,352,351; 5,385,846; 5,395,504; 5,469,846; 5,508,171; 5,508,203; and 5,509,410: German Patent Specification 3,228,542: European Patent Specifications: 206,218; 230,472; 241,309; 255,291; and, 471,986: and, Japanese Published Patent Applications JP 63-128,252 and 63-111,453. There are also the methods and apparatus described in: Talbott, et al, “A New Microchemical Approach to Amperometric Analysis,” Microchemical Journal, Vol. 37, pp. 5-12 (1988); Morris, et al, “An Electrochemical Capillary Fill Device for the Analysis of Glucose Incorporating Glucose Oxidase and Ruthenium (III) Hexamine as Mediator, Electroanalysis,” Vol. 4, pp. 1-9 (1992); Cass, et al, “Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of Glucose,” Anal. Chem., Vol. 56, pp. 667-671 (1984); Zhao, “Contributions of Suspending Medium to Electrical Impedance of Blood,” Biochimica et Biophysica Acta, Vol. 1201, pp. 179-185 (1994); Zhao, “Electrical Impedance and Haematocrit of Human Blood with Various Anticoagulants,” Physiol. Meas., Vol. 14, pp. 299-307 (1993); Muller, et al., “Influence of Hematocrit and Platelet Count on Impedance and Reactivity of Whole Blood for Electrical Aggregometry,” Journal of Pharmacological and Toxicological Methods, Vol. 34, pp. 17-22 (1995); Preidel, et al, “In Vitro Measurements with Electrocatalytic Glucose Sensor in Blood,” Biomed. Biochim. Acta, Vol. 48, pp. 897-903 (1989); Preidel, et al, “Glucose Measurements by Electrocatalytic Sensor in the Extracorporeal Blood Circulation of a Sheep,” Sensors and Actuators B, Vol. 2, pp.257-263 (1990); Saeger, et al, “Influence of Urea on the Glucose Measurement by Electrocatalytic Sensor in the Extracorporeal Blood Circulation of a Sheep,” Biomed. Biochim. Acta, Vol. 50, pp. 885-891 (1991); Kasapbasioglu, et al, “An Impedance Based Ultra-Thin Platinum Island Film Glucose Sensor,” Sensors and Actuators B, Vol. 13-14, pp. 749-751 (1993); Beyer, et al, “Development and Application of a New Enzyme Sensor Type Based on the EIS-Capacitance Structure for Bioprocess Control,” Biosensors & Bioelectronics, Vol. 9, pp. 17-21 (1994); Mohri, et al, “Characteristic Response of Electrochemical Nonlinearity to Taste Compounds with a Gold Electrode Modified with 4-Aminobenzenethiol,” Bull. Chem. Soc. Jpn., Vol. 66, pp. 1328-1332 (1993); Cardosi, et al, “The Realization of Electron Transfer from Biological Molecules to Electrodes,” [0002] Biosensors Fundamentals and Applications, chapt. 15 (Turner, et al, eds., Oxford University Press, 1987); Mell, et al, “Amperometric Response Enhancement of the Immobilized Glucose Oxidase Enzyme Electrode,” Analytical Chemistry, Vol. 48, pp. 1597-1601 (September 1976); Mell, et al, “A Model for the Amperometric Enzyme Electrode Obtained Through Digital Simulation and Applied to the Immobilized Glucose Oxidase System,” Analytical Chemistry, Vol. 47, pp. 299-307 (February 1975); Myland, et al, “Membrane-Covered Oxygen Sensors: An Exact Treatment of the Switch-on Transient,” Journal of the Electrochemical Society, Vol. 131, pp. 1815-1823 (August 1984); Bradley, et al, “Kinetic Analysis of Enzyme Electrode Response,” Anal. Chem., Vol. 56, pp. 664-667 (1984); Koichi, “Measurements of Current-Potential Curves, 6, Cottrell Equation and its Analogs. What Can We Know from Chronoamperometry?” Denki Kagaku oyobi Kogyo Butsuri Kagaku, Vol. 54, no.6, pp. 471-5 (1986); Williams, et al, “Electrochemical-Enzymatic Analysis of Blood Glucose and Lactate,” Analytical Chemistry, Vol. 42, no. 1, pp. 118-121 (January 1970); and, Gebhardt, et al, “Electrocatalytic Glucose Sensor,” Siemens Forsch.-u. Entwickl.-Ber. Bd., Vol. 12, pp. 91-95 (1983). This listing is not intended as a representation that a complete search of all relevant prior art has been conducted, or that no better references than those listed exist. Nor should any such representation be inferred.
  • DISCLOSURE OF THE INVENTION
  • According to one aspect of the invention, an apparatus for determining the concentration of a medically significant component of a biological fluid comprises a cell for receiving a sample of the fluid. The cell supports a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The apparatus further comprises an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The instrument includes an assessment controller for applying across the first and second terminals of the instrument a first signal, determining a first response of the cell to the first signal, and determining based upon the first response whether to proceed with the determination of the concentration of the medically significant component of the biological fluid. [0003]
  • According to another aspect of the invention, an apparatus for determining the concentration of a medically significant component of a biological fluid comprises a cell for receiving a sample of the fluid. The cell supports a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The apparatus further comprises an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The instrument includes an assessment controller for applying across the first and second terminals of the instrument a first signal, determining a first correction value in response of the cell to the first signal, assessing the reaction of the medically significant component with the chemistry and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample. [0004]
  • According to another aspect of the invention, an apparatus for determining the concentration of a medically significant component of a biological fluid comprises a cell for receiving a sample of the fluid. The cell supports a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The apparatus further comprises an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The instrument includes an assessment controller for applying across the first and second terminals of the instrument a first signal, determining the identity of the sample in response of the cell to the first signal, and producing an indication of the identity of the sample. [0005]
  • According to yet another aspect of the invention, a method for determining the concentration of a medically significant component of a biological fluid comprises providing a cell for receiving a sample of the fluid, and providing on the cell a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The method further comprises providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The method further comprises providing in the instrument an assessment controller, causing the assessment controller to apply across the first and second terminals of the instrument a first signal, causing the assessment controller to determine a first response of the cell to the first signal, and causing the assessment controller to determine, based upon the first response, whether to proceed with the determination of the concentration of the medically significant component of the biological fluid. [0006]
  • According to a further aspect of the invention, a method for determining the concentration of a medically significant component of a biological fluid comprises providing a cell for receiving a sample of the fluid, and providing on the cell a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The method further comprises providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The method further comprises providing in the instrument an assessment controller, causing the assessment controller to apply across the first and second terminals of the instrument a first signal, to determine a first correction value in response to the first signal, to assess the reaction of the medically significant component with the chemistry, and to combine the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample. [0007]
  • According to a further aspect of the invention, a method for determining the concentration of a medically significant component of a biological fluid comprises providing a cell for receiving a sample of the fluid, and providing on the cell a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed. The method further comprises providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell. Placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permits the instrument to assess the reaction. The method further comprises providing in the instrument an assessment controller for applying across the first and second terminals of the instrument a first signal, determining the identity of the sample in response of the cell to the first signal, and producing an indication of the identity of the sample. [0008]
  • Illustratively, the first signal comprises a signal having an AC component. Further illustratively, the first signal comprises an AC signal. [0009]
  • Additionally illustratively, the method of, and apparatus for, determining the correction value, the method of, and apparatus for, determining the identity of the sample, and the method of, and apparatus for, determining whether to proceed with the determination of the concentration of the medically significant component of the biological fluid comprise the step of, and apparatus for, determining the impedance across terminals of the cell.[0010]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention may best be understood by referring to the following detailed description and accompanying drawings which illustrate the invention. In the drawings: [0011]
  • FIG. 1 illustrates a schematic diagram of a circuit useful in understanding the invention; [0012]
  • FIG. 2 illustrates a partly block and partly schematic diagram of an instrument constructed according to the present invention; [0013]
  • FIG. 3 illustrates a partly block and partly schematic diagram of another instrument constructed according to the present invention; [0014]
  • FIG. 4 illustrates a partly block and partly schematic diagram of another instrument constructed according to the present invention; [0015]
  • FIG. 5 illustrates glucose concentration results achieved in several forty second glucose concentration determinations with standard glucose test solutions; [0016]
  • FIG. 6 illustrates glucose concentration results achieved in several ten second glucose concentration determinations with standard glucose test solutions; and, [0017]
  • FIG. 7 illustrates glucose concentration results achieved in several ten second glucose concentration determinations with standard glucose test solutions.[0018]
  • DETAILED DESCRIPTIONS OF ILLUSTRATIVE EMBODIMENTS
  • Instruments are known which employ devices such as disposable mediated amperometric cells (sometimes referred to hereinafter as biosensors) which provide, for example, characteristic electrical impedances when treated with biological fluids, blood or urine for example, having certain corresponding concentrations of biologically significant components, such as, for example, glucose. Such measurement systems are known to be susceptible to variations in the temperature of the biological fluids and to interference by the presence in the biological fluids of other components, known and sometimes referred to hereinafter as interferrents. In many cases, these sources of error have effects on the biosensor output of the same order of magnitude as the concentration of the component, measurement of which is sought. It may not be possible to develop a biosensor which will measure only the concentration of the component whose concentration is sought in the presence of these sources of error. An example of this phenomenon is the hematocrit interference in a biosensor of the type described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846 and, 5,508,171, with the determination of the glucose concentration of whole blood. Since all whole blood contains red blood cells, and since the hematocrit can vary over a fairly wide range in individuals who might wish to rely upon such biosensor testing, the utility of a hematocrit-compensated glucose biosensor is clear. [0019]
  • Equally problematic is the sensitivity of many commercially available biosensors to the volume of the dopant biological fluid. In the case of glucose concentration of whole blood, for example, many presently available biosensors are sensitive to the volume of blood with which they are doped for determination of glucose concentration. Since many of the tests which are presently being conducted using biosensors are being conducted by people who are monitoring, for example, the glucose concentrations of their own blood, the volumes of the blood samples with which the biosensors are doped are not predictable with a great degree of certainty. [0020]
  • While the careful design of the biosensor itself can prevent some errors, such as undoped biosensors, substantially underdoped biosensors and substantially overdoped biosensors, for example, it cannot practically take into account the full range of doping volume variation. [0021]
  • We have discovered that measurement of the real component or the imaginary component, or both, of the AC impedance of an appropriately designed biosensor provides reasonable insight into sample temperature and the concentrations of certain physical and chemical interferrents. In biosensors of the general types described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; 5,508,171; 5,437,999; and, U.S. Ser. No. 08/985,840, filed Dec. 5, 1997 and assigned to the same assignee as this application, such physical interferrents include, for example, hematocrit, and such chemical interferrents include, for example, bilirubin, uric acid and oxygen. We have discovered that measurement of the real component or the imaginary component, or both, of the AC impedance of an appropriately designed biosensor also provides reasonable insight into the volume of a sample with which the biosensor is doped, and the identity of that sample; that is, whether the sample is a sample of blood or some other bodily fluid, or a sample of some control used, for example, in calibration or troubleshooting of the instrument. We have discovered that sample temperature, the concentrations of such physical and chemical interferrents, the identity of the sample and the sample volume can be ascertained at judiciously selected AC frequencies, providing reasonable isolation of the determinations of the effects of sample temperature, interferrent concentrations and sample volume and identity from each other, and thereby increasing the accuracy of, for example, the interferrent effect determinations, and their subsequent correction out of the indicated glucose concentration. We have also found that the speeds at which acceptably accurate readings of corrected glucose concentration are obtained can be markedly reduced. The appropriately designed biosensor must be able to tolerate the determination of these AC impedances, using, for example, AC signals having peak amplitudes in the range of a few tens of millivolts, without jeopardizing the measurement of the glucose concentration, which the biosensor will perform either before, concurrently with, or after it performs the AC impedance determination. [0022]
  • By way of example only, we have determined that in biosensors of the type described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; 5,508,171; 5,437,999; and, U.S. Ser. No. 08/985,840, it is possible to employ a low-magnitude, for example, less than about 40 mV rms or so, AC signal in the range of less than about 0.1 Hz to 10 KHz or so with no DC offset to compensate for sample temperature, hematocrit, bilirubin concentration, uric acid concentration and oxygen concentration, and to determine identity of the sample with which the biosensor is dosed, and adequacy of dosed blood sample volume for a test for glucose concentration. We have determined, for example, that at about 1300 Hz, both hematocrit and glucose concentration have relatively little effect on AC impedance, while sample volume and sample identity have relatively substantially greater, fairly readily ascertainable, effects on AC impedance. This provides an ideal way to determine the adequacy of the sample volume with which the biosensor is dosed and the identity of the sample. If the sample is determined to be blood, and the sample volume is determined to be inadequate to test meaningfully for hematocrit, glucose concentration, and so on, the test is discontinued and the user is notified of the discontinuance of the test. [0023]
  • We have determined that the combined effect of sample temperature and hematocrit can fairly effectively be isolated from other physical and chemical interferrents of interest using frequencies in the range of from about 2 KHz to about 10 KHz. So, for example, once the adequacy of the sample volume for test has been established, a 2 KHz signal can be applied to the biosensor and the real and imaginary components of impedance of the biosensor/sample system can be determined. This indicated impedance can be adjusted by an experimentally determined scaling factor governed by, among other things, the characteristics of the biosensor and the instrument, and combined with an indicated glucose concentration to arrive at a glucose concentration compensated for the combined effects of sample temperature and hematocrit. [0024]
  • These determinations illustratively are made before the amperometric determination of the glucose concentration of the blood sample. DC offset may be avoided, if necessary, to reduce the likelihood of affecting the amperometric determination of the glucose concentration which, it must be remembered, is going to be conducted subsequently in the illustrated embodiments. Similar procedures can be conducted, again in the illustrated embodiments before the amperometric determination of the glucose concentration, to determine the concentrations of other interferrents with chemistry for the glucose concentration determination, such as bilirubin, uric acid and oxygen. These determinations are conducted at frequencies at which their effects upon each other and upon other physical and chemical interferrents will be optimally decoupled from each other. For example, if, in the chemistry system of the amperometric cell, bilirubin and uric acid are chemical interferrents with each other, a frequency or range of frequencies should be selected for the bilirubin concentration determination, which frequency or range of frequencies is optimally unaffected by the concentrations of uric acid and any other physical and chemical interferrents in the sample. Similarly, a frequency must be selected for the uric acid concentration determination which is optimally unaffected by the concentrations of bilirubin and any other physical and chemical interferrents in the sample. In each case, however, the determined impedance is converted either directly or via a concentration determination which can also be displayed to the user or stored in the instrument for future reference, to a correction factor for application to the indicated glucose concentration in order to arrive at a more accurate glucose concentration determination. [0025]
  • The methods and apparatus are believed best understood by consideration of the equivalent circuit of an amperometric sensor of the type described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; 5,508,171; 5,437,999; and, U.S. Ser. No. 08/985,840. That equivalent circuit is illustrated in FIG. 1. In FIG. 1, a resistor [0026] 20 represents the uncompensated resistance of the amperometric cell, a capacitor 22 represents the capacitance attributable to the double layer of charge on the dosed cell with potential applied, a resistor 24 represents the charge transfer resistance of the cell's chemistry, and a resistor 26 and a capacitor 28 represent the so-called Warburg impedance. While the lumped electrical parameter models of other types of amperometric sensors may differ from the model illustrated in FIG. 1, similar analyses of those models will yield conclusions similar to those reached here, namely, that the real and imaginary components of the cells' or biosensors' electrical impedances provide techniques for determining quantitatively with some reasonable degree of accuracy the effects of interferrent concentrations, sample volume and sample identity on the concentration of a biologically significant component of a sample of a body fluid. These conclusions give the instrument and cell designer useful techniques for determining the adequacy of the volume of a sample applied to a biosensor, for determining the identity of the sample, and for correcting the indicated concentration of a biologically significant component of the sample for the concentration(s) of such interferrent(s) so that the effects of the concentration(s) of such interferrent(s) can be reduced in the indicated concentration of the biologically significant component of interest to provide more accurate information on the concentration of the biologically significant component of interest.
  • Blood sample studies analyzing the magnitudes of the real and imaginary components of the impedance of the equivalent circuit of FIG. 1 have established that in the range of about 1 KHz-10 KHz, there is very little dependence of the imaginary component of impedance on glucose concentration of the sample, while there is sufficient dependence of the magnitude of impedance on the combination of sample temperature and hematocrit to permit a sample first to be subjected to a low-magnitude AC signal in this frequency range, the magnitude of impedance to be determined, and a combined sample temperature/hematocrit correction factor to be combined with the indicated glucose concentration determined using the amperometry techniques described in, for example, U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; 5,508,171; 5,437,999; and, U.S. Ser. No. 08/985,840, to yield a glucose concentration corrected for the combined effects of sample temperature and hematocrit. Similar techniques can be employed to determine sample volume and sample type. The sample volume determination, however, ordinarily will result in a go-no go determination for the remainder of the assay. The sample type determination ordinarily will determine whether the instrument proceeds to a glucose concentration subroutine including, for example, determination of interferrent correction factors, or to a diagnostic subroutine used to set up the instrument for a later glucose concentration determination. [0027]
  • Referring to FIG. 2, a strip connector [0028] 30 of the general type illustrated in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and, 5,508,171, makes contact between a disposable amperometric sensor cell or biosensor 31 of the general type illustrated in those patents and the instrument 32. The indicated glucose concentration functionality of the instrument 32 is largely as described in those patents. However, additional functions, namely, the correction of the indicated glucose concentration for blood sample volume and the combined effect of sample temperature and hematocrit of the blood sample under test, are implemented in the instrument 32 according to the present invention. It has been established that eight bit analog-to-digital (A/D) and digital-to-analog (D/A) computational power permits the instrument 32 to achieve accuracies in the range of about one-half percent or less. A first terminal 34-1 of a connector 34 is coupled through a 10KΩ resistor to a terminal 36-1 of a switch 36. A terminal 36-2 of switch 36 is coupled to the inverting, or −, input terminal of a difference amplifier 38. An output terminal of amplifier 38 is coupled to a terminal 36-3 of switch 36. A terminal 36-4 of switch 36 is coupled to a terminal 34-2 of connector 34. DC excitation across the biosensor 31 is established by the output of amplifier 38. For accurate setting of DC excitation of the biosensor 31, feedback from terminal 34-1 is returned to the −input terminal of amplifier 38. Terminals 34-1 and 34-2 contact a common electrode on biosensor 31 for enhanced accuracy of excitation.
  • A terminal [0029] 34-3 of connector 34 is coupled to a −input terminal of a difference amplifier 42. An output terminal of amplifier 42 is coupled through a 7.5KΩ resistor 44 to the −input terminal thereof. The non-inverting, or +, input terminal of amplifier 42 is coupled to the common of the circuit power supply. An output terminal of amplifier 42 is coupled to an input terminal of a thirteen bit A/D converter 46. An output port of A/D converter 46 is coupled to an input port of a processor 48 with supporting functions which performs the indicated glucose measurement functions as described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and, 5,508,171. An output port of processor 48 is coupled to an input port of an eight bit D/A converter 50. An output terminal of D/A converter 50 is coupled to the +input terminal of amplifier 38. The functions of components 38, 42, 46, 48 and 50 illustratively, although not by any means necessarily, are embodied in an application-specific integrated circuit (ASIC) 52. The remaining, hematocrit compensating and sample volume determining functions of instrument 32 illustratively are embodied in a NEC μPD78054 microprocessor (μP) 54 which also has input A/D and output D/A converting capabilities 56 and 58, respectively. In FIG. 2, the input A/D and output D/A capabilities 56, 58 are illustrated separately from the processing functions of μP 54 for purposes of clarity. Terminal 36-4 of switch 36 is coupled to an input terminal of A/D converter 56. The output terminal of amplifier 42 is coupled to an input terminal of A/D converter 56. The output terminal of D/A converter 58 is coupled through a 0.1 μF capacitor and a 400KΩ resistor in series to terminal 36-1 of switch 36 for AC excitation in this example. Here, an AC excitation signal is summed with the DC excitation provided by amplifier 38.
  • The calculations of the real and imaginary components of the AC impedance of the biosensor cell [0030] 31 coupled to terminals 34-1, -2 and -3 are made by exciting terminal 34-2 of connector 34 at the desired frequency, for example, 1300 Hz or 10 KHz, at which the parameter to be determined, be it sample identity or volume or hematocrit, or whatever other parameter is of interest and can be determined this way, varies with sufficient magnitude and phase and is optimally uncoupled from, that is, is not interfered with by, the concentrations of other components of the blood on the cell 31.
  • The calculation of the real and imaginary components of the cell [0031] 31 impedance from the AC excitation and response are achieved as follows. The eight bit excitation samples are N values E(0), E(1), E(2), . . . E(N−1). These values are developed by sampling the excitation by A/D converter 56. The eight bit response samples are N values V(0), V(1), V(2), . . . V(N−1). These values are A/D converted by A/D converter 56 and returned to the processor function of μP 54. Terminal 34-2 of connector 34 provides the common terminal against which these values are referenced. A scale factor K accounts for various gain factors involved in excitation and measurement. The excitation frequency is F Hz. The sample rate is MF, where M illustratively has a value of 5 or more. The period between samples is thus 1/MF sec. Arrays S(n) and C(n) of sine and cosine values are calculated and stored in program memory in μP 54 according to the following relations:
  • S(n)=sin(2πF(n/MF)), n=0 to (N−1)
  • C(n)=cos(2πF(n/MF)), n=0 to (N−1).
  • The real and imaginary components of excitation are calculated as follows: [0032] Ere = n = 0 N - 1 S ( n ) E ( n )
    Figure US20030064525A1-20030403-M00001
  • The real and imaginary components of response are calculated as [0033] Eim = n = 0 N - 1 C ( n ) E ( n ) follows: Vre = n = 0 N - 1 S ( n ) V ( n ) Vim = n = 0 N - 1 C ( n ) V ( n )
    Figure US20030064525A1-20030403-M00002
  • The magnitudes of the excitation and response are calculated as follows: [0034]
  • E=(Ere 2 +Eim 2)1/2,
  • V=(Vre 2 +Vim 2)1/2.
  • The magnitude of the strip impedance can then be calculated: [0035]
  • |Z|=KE/V.
  • The phase of the strip impedance can also be calculated: [0036] arctan ( Vim Vre ) - arctan ( Eim Ere ) = Z
    Figure US20030064525A1-20030403-M00003
  • Thus, a measurement of actual glucose concentration using an instrument [0037] 32 of the type illustrated in FIG. 2 proceeds as follows. A sample of blood is applied to the biosensor 31. Immediately after the instrument 32's electronics detect the deposit of the droplet on the biosensor 31, an AC signal having a frequency of, for example, 1300 Hz is applied across terminals 34-2-34-3 of connector 34 and the resulting current is indirectly sampled by μP 54 by measuring the excitation and response voltages and using the scale factor to obtain current. The impedance magnitude and phase angle are calculated. Using these values, a look-up table in the μP 54's program memory is consulted to ascertain the nature of the sample and, if blood, whether there is sufficient volume in the blood sample to proceed with the glucose determination phase of the assay. If not, the assay is terminated and this outcome is displayed on the instrument 32's display. If there is sufficient volume to continue with the glucose determination, an AC signal at another frequency, for example, 10 KHz, is applied across terminals 34-2-34-3 of connector 34 and the resulting current is sampled by μP 54. The impedance and phase angle are again calculated at this second frequency. A second look-up table in the μP 54's program memory is consulted for an indicated glucose-to-actual glucose correction factor. This correction factor may be a constant, for example, zero, for indicated glucose concentrations less than a first indicated glucose concentration, and variable for indicated glucose concentrations greater than that first indicated glucose concentration, for example. In any event, that correction is stored, and the determination of the indicated glucose concentration proceeds generally as described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and 5,508,171, for example. Once the indicated glucose concentration has been obtained, the correction is then retrieved and applied to the indicated glucose concentration to arrive at the actual glucose concentration which is displayed on the instrument 32's display and/or stored in the instrument 32's memory.
  • Another embodiment of the invention is illustrated in partly block and partly schematic form in FIG. 3. There, an instrument [0038] 132 includes a strip connector 130 of the same general type as strip connector 30 illustrated in FIG. 2. Strip connector 130 is designed to make contact to a biosensor 31. A first terminal 134-1 of a connector 134 is coupled through a 10KΩ resistor to a terminal 136-1 of a switch 136. A terminal 136-2 of switch 136 is coupled to the −input terminal of a difference amplifier 138. An output terminal of amplifier 138 is coupled to a terminal 136-3 of switch 136. A terminal 136-4 of switch 136 is coupled to a terminal 134-2 of connector 134. DC excitation across the biosensor 31 is established by the output of amplifier 138. For accurate setting of DC excitation of the biosensor 31, feedback from terminal 134-1 is returned to the −input terminal of amplifier 138. Terminals 134-1 and 134-2 contact a common electrode on biosensor 31 for enhanced accuracy of excitation. A terminal 134-3 of connector 134 is coupled to a −input terminal of a difference amplifier 142. An output terminal of amplifier 142 is coupled through a 7.5KΩ resistor 144 to the −input terminal thereof. The +input terminal of amplifier 142 is coupled to the common of the circuit power supply. An output terminal of amplifier 142 is coupled to an input terminal of a thirteen bit A/D converter 146. An output port of A/D converter 146 is coupled to an input port of a processor 148 with supporting functions which performs the indicated glucose measurement functions as described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and, 5,508,171. An output port of processor 148 is coupled to an input port of an eight bit D/A converter 150. An output terminal of D/A converter 150 is coupled to the +input terminal of amplifier 138. The functions of components 138, 142, 146, 148 and 150 illustratively, although not by any means necessarily, are embodied in an ASIC 152.
  • The real and imaginary components of the AC impedance of the biosensor cell [0039] 31 coupled to terminals 134-1, -2 and -3 are calculated by excitation applied between terminals 134-2 and 134-3 of connector 134 at the desired frequencies, for example, by sweeping the low-magnitude AC voltage source 150 through a suitable frequency range of, for example, 0.1 Hz-100 Hz or 10 Hz-10 KHz, throughout some portion or all of which the parameter to be determined, be it sample identity, sample volume, sample temperature/hematocrit, oxygen concentration in the sample, or whatever other parameter is of interest and can be determined this way, varies with sufficient magnitude and phase and is optimally uncoupled from, that is, independent from, the concentrations of other components of the sample on the cell 31.
  • In the embodiment illustrated in FIG. 3, this low magnitude AC voltage excitation is summed at a summing junction [0040] 152 with an optional DC offset 156 which may be utilized if it aids the determination of the concentration of the interferent of interest. In the illustrated embodiment, the AC voltage and DC offset are both generated under the control of a microprocessor (μP) 158 which may be the same μP which manages the above-mentioned meter 132 functions, or may be a separate μP. The μP 158 will typically be programmed to sweep the AC voltage source 150 and adjust the DC offset, depending upon which interferent's concentration the μP 158 is determining. In this manner, each interferent's concentration may readily be ascertained in the optimum frequency range and at the optimum DC offset for isolation of that particular interferent's concentration. If μP 158 is used to control sweep and offset, a separate external connection 160 need not be provided from the summing junction 152 to the μP 158. Since μP 158 is going to determine the frequency response of the cell 31, the frequencies associated with the determined frequency response can be stored in the μP 158's memory as the frequency response is being determined. If some other mechanism is employed in the determination of the frequency response, however, it may be necessary to provide feedback 160 to the μP 158 of the output frequency of source 150, as well as the level of the DC offset 156. In any event, isolation of the summing junction 152 and any feedback path 160 from the cell 31 is provided by an operational amplifier 164 whose input is coupled to summing junction 152, and whose output is coupled through a suitably valued resistor into the feedback path of amplifier 138 to drive the cell 31. Similarly, isolation of the cell 31 from the frequency response-determining input of μP 158 is provided by an operational amplifier 166 coupled to the output of amplifier 142. Determination of the frequency response of the cell 31 proceeds in known fashion, for example, by fast Fourier transform (FFT) or other known μP 158-implemented frequency response determining mechanism. The frequency response characteristic of the cell 31 is then compared to the stored frequency response characteristic for the specific interferent whose concentration is being determined, an interferent concentration is determined, and an associated correction value for the indicated glucose concentration is determined and either stored for later use in correcting the indicated glucose concentration or immediately combined with an indicated glucose concentration to achieve a corrected glucose concentration.
  • Again, ordinarily, the instrument [0041] 132 will first determine the various frequency responses of the cell 31 in the various optimally uncoupling frequency ranges, with the various optimally uncoupling AC amplitudes and with the various optimally uncoupling DC offsets, followed by the determination of the indicated glucose concentration, followed by correction of the indicated glucose concentration for the thus-determined concentrations of the various interferrents. However, and as previously noted, it may be desirable under certain circumstances and with certain interferrents to have the instrument 132 first determine the indicated concentration of glucose before the concentrations of these interferrents are determined.
  • Another embodiment of the invention is illustrated in partly block and partly schematic form in FIG. 4. There, an instrument [0042] 232 includes a strip connector 230 of the same general type as strip connector 30 illustrated in FIG. 2. Strip connector 230 is designed to make contact to a biosensor 31. A first terminal 234-1 of a connector 234 is coupled to the −input terminal of a difference amplifier 238. An output terminal of amplifier 238 is coupled to a terminal 234-2 of connector 234. DC excitation across the biosensor 31 is established by the output of amplifier 238. For accurate setting of DC excitation of the biosensor 31, feedback from terminal 234-1 is returned to the −input terminal of amplifier 238. Terminals 234-1 and 234-2 contact a common electrode on biosensor 31 for enhanced accuracy of excitation. A terminal 234-3 of connector 234 is coupled to a −input terminal of a difference amplifier 242. An output terminal of amplifier 242 is coupled through a 8.25KΩ resistor 244 to the −input terminal thereof The +input terminal of amplifier 242 is coupled to a 1.667V reference. An output terminal of amplifier 242 is coupled to an input terminal of a fourteen bit A/D converter 246. An output port of A/D converter 246 is coupled to an input port of a processor 248 with supporting functions which performs the indicated glucose measurement functions as described in U.S. Pat. Nos. 5,243,516; 5,288,636; 5,352,351; 5,385,846; and, 5,508,171. An output port of processor 248 is coupled to an input port of a thirteen bit D/A converter 250. Amplifier 238 and D/A converter 250 illustratively are integrated into a single device. Amplifier 238 has an open circuit shutdown mode, permitting switches 36, 136 of the embodiments illustrated in FIGS. 2-3 to be eliminated and thereby simplifying the circuit somewhat. Otherwise, the circuit illustrated in FIG. 4 functions in much the same way as the circuits illustrated in FIGS. 2-3. An output terminal of D/A converter 250 is coupled to the +input terminal of amplifier 238. The functions of components 238, 242, 246, 248 and 250 illustratively, although not by any means necessarily, are embodied in an ASIC 252. The accuracy and resolution of D/A converter 250 and A/D converter 246 enable both AC and DC strip current measurements and thus a circuit simplification.
  • Again, it should be understood that the physical and chemical design characteristics of a particular cell will, to a large extent, determine the electrical characteristics of that cell. Therefore, those physical and chemical design characteristics will, to at least the same extent, determine that cell's response to each interferent, to different sample types, and to different sample volumes. It is not possible to predict, for example, in what frequency range hematocrit's concentration will be optimally uncoupled from uric acid's or bilirubin's without reference to the specific physical and chemical characteristics of that cell. Some investigation will be required to determine these optimum frequency ranges. However, the investigation will be relatively routine once the physical and chemical characteristics of the cell are known. [0043]
  • The reduction in the time required to achieve a compensated indication of the glucose concentration of blood can best be appreciated by referring to FIGS. [0044] 5-7. FIG. 5 illustrates glucose concentration results achieved in several forty second glucose concentration determinations with standard glucose test solutions. The tests whose results are illustrated in FIG. 5 were performed without impedance determination and compensation for the combined effects of temperature and hematocrit described above, but were compensated for temperature and hematocrit using prior art techniques. FIG. 6 illustrates glucose concentration results achieved in several ten second glucose concentration determinations with standard glucose test solutions. The tests whose results are illustrated in FIG. 6 were performed without impedance determination and compensation for the combined effects of temperature and hematocrit described above, but again were compensated for temperature and hematocrit using prior art techniques. FIG. 7 illustrates glucose concentration results achieved in several ten second glucose concentration determinations with standard glucose test solutions. The tests whose results are illustrated in FIG. 7 were performed using impedance determination and compensation for the combined effects of temperature and hematocrit described above. It will be appreciated from a comparison of these Figs. that the use of the impedance determination and compensation technique described above permits a reduction by a factor of four in the time required to achieve comparable glucose concentration determination in these test solutions.

Claims (51)

  1. 1. An apparatus for determining the concentration of a medically significant component of a biological fluid, the apparatus comprising a cell for receiving a sample of the fluid, the cell supporting a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, the instrument including an assessment controller for applying across the first and second terminals of the instrument a first signal, determining a first correction value in response of the cell to the first signal, assessing the reaction of the medically significant component with the chemistry and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  2. 2. The apparatus of claim 1 wherein the assessment controller comprises an assessment controller for applying across the first and second terminals a signal having an AC component.
  3. 3. The apparatus of claim 2 wherein the assessment controller comprises an assessment controller for applying across the first and second terminals an AC signal.
  4. 4. The apparatus of claim 1 wherein the instrument further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  5. 5. The apparatus of claim 4 wherein the assessment controller for determining a first correction value in response to the first signal comprises an assessment controller for feeding back a portion of the first signal appearing at the third terminal.
  6. 6. The apparatus of claim 5 wherein the assessment controller for assessing the reaction of the medically significant component with the chemistry comprises an assessment controller for applying across a pair of the first, second and third terminals of the instrument a second signal and assessing the reaction of the medically significant component with the chemistry in response to the second signal.
  7. 7. The apparatus of claim 1 wherein the assessment controller for applying across the first and second terminals of the instrument a first signal comprises an assessment controller for applying across the first and second terminals of the instrument a second signal, determining a second response to the second signal, the second response determining if the assessment controller proceeds with the application of the first signal.
  8. 8. The apparatus of claim 7 wherein the assessment controller for applying across the first and second terminals of the instrument a second signal comprises an assessment controller for applying across the first and second terminals a signal having an AC component.
  9. 9. The apparatus of claim 8 wherein the assessment controller for applying across the first and second terminals of the instrument a second signal comprises an assessment controller for applying across the first and second terminals an AC signal.
  10. 10. The apparatus of claim 2 wherein the instrument further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  11. 11. The apparatus of claim 10 wherein the assessment controller for determining a first correction value in response to the first signal comprises an assessment controller for feeding back a portion of the first signal appearing at the third terminal.
  12. 12. The apparatus of claim 11 wherein the assessment controller for assessing the reaction of the medically significant component with the chemistry comprises an assessment controller for applying across a pair of the first, second and third terminals of the instrument a second signal and assessing the reaction of the medically significant component with the chemistry in response to the second signal.
  13. 13. An apparatus for determining the concentration of a medically significant component of a biological fluid, the apparatus comprising a cell for receiving a sample of the fluid, the cell supporting a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, the instrument including an assessment controller for applying across the first and second terminals of the instrument a first signal having an AC component, determining a first response of the cell to the first signal, and determining based upon the first response whether to proceed with the determination of the concentration of the medically significant component of the biological fluid.
  14. 14. The apparatus of claim 13 wherein the assessment controller for applying across the first and second terminals of the instrument a first signal comprises an assessment controller for applying across the first and second terminals an AC signal.
  15. 15. The apparatus of claim 13 wherein the assessment controller for applying across the first and second terminals of the instrument a first signal comprises an assessment controller for applying across the first and second terminals of the instrument a second signal, determining a first correction value in response to the second signal, and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  16. 16. The apparatus of claim 15 wherein the assessment controller for applying across the first and second terminals a second signal comprises an assessment controller for applying across the first and second terminals a second signal having an AC component.
  17. 17. The apparatus of claim 16 wherein the assessment controller for applying across the first and second terminals a second signal comprises an assessment controller for applying across the first and second terminals an AC second signal.
  18. 18. The apparatus of claim 17 wherein the instrument further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  19. 19. The apparatus of claim 18 wherein the assessment controller for determining a first correction value in response to the second signal comprises an assessment controller for feeding back a portion of the second signal appearing at the third terminal.
  20. 20. The apparatus of claim 19 wherein the assessment controller for assessing the reaction of the medically significant component with the chemistry comprises an assessment controller for applying across a pair of the first, second and third terminals of the instrument a third signal and assessing the reaction of the medically significant component with the chemistry in response to the second signal.
  21. 21. The apparatus of claim 15 wherein the instrument further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  22. 22. The apparatus of claim 21 wherein the assessment controller for determining a first correction value in response to the second signal comprises an assessment controller for feeding back a portion of the second signal appearing at the third terminal.
  23. 23. The apparatus of claim 22 wherein the assessment controller for assessing the reaction of the medically significant component with the chemistry comprises an assessment controller for applying across a pair of the first, second and third terminals of the instrument a third signal and assessing the reaction of the medically significant component with the chemistry in response to the third signal.
  24. 24. A method for determining the concentration of a medically significant component of a biological fluid, the method comprising providing a cell for receiving a sample of the fluid, providing on the cell a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, including in the instrument an assessment controller, causing the assessment controller to apply across the first and second terminals of the instrument a first signal having an AC component, causing the assessment controller to determine a first response of the cell to the first signal, and causing the assessment controller to determine based upon the first response whether to proceed with the determination of the concentration of the medically significant component of the biological fluid.
  25. 25. The method of claim 24 wherein the step of applying across the first and second terminals of the instrument a first signal comprises applying across the first and second terminals of the instrument a second signal, determining a first correction value in response to the second signal and combining the first correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  26. 26. The method of claim 25 wherein the step of applying across the first and second terminals a second signal comprises applying across the first and second terminals an AC second signal.
  27. 27. The method of claim 26 wherein providing an instrument having first and second terminals complementary to the first and second terminals of the cell comprises providing an instrument having first, second and third terminals, placement of the first and second terminals of the cell in contact with the first, second and third terminals of the instrument permitting the instrument to assess the reaction.
  28. 28. The method of claim 27 wherein determining the second response of the cell to the second signal and converting that second response to a first correction value comprises feeding back a portion of the second signal appearing at the third terminal.
  29. 29. The method of claim 28 wherein assessing the reaction of the medically significant component with the chemistry comprises applying across a pair of the first, second and third terminals of the instrument a third signal and assessing the reaction of the medically significant component with the chemistry in response to the third signal.
  30. 30. The method of claim 24 wherein providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell comprises providing an instrument having first, second and third terminals, placement of the first and second terminals of the cell in contact with the first and second terminal of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  31. 31. The method of claim 30 wherein determining the correction value in response to the second signal comprises feeding back a portion of the second signal appearing at the third terminal.
  32. 32. The method of claim 31 wherein assessing the reaction of the medically significant component with the chemistry comprises applying across a pair of the first, second and third terminals of the instrument a third signal and assessing the reaction of the medically significant component with the chemistry in response to the third signal.
  33. 33. A method for determining the concentration of a medically significant component of a biological fluid, the method comprising providing a cell for receiving a sample of the fluid, providing the cell with a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, providing in the instrument an assessment controller, causing the assessment controller to apply across the first and second terminals of the instrument a first signal, determining a first correction value in response to the first signal, assessing the reaction of the medically significant component with the chemistry, and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  34. 34. The method of claim 33 wherein providing an instrument having first and second complementary terminals comprises providing an instrument having first, second and third terminals, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument.
  35. 35. The method of claim 34 wherein determining a first response of the cell to the first signal and converting that first response to a first correction value comprises feeding back a portion of the first signal appearing at the third terminal.
  36. 36. The method of claim 35 wherein assessing the reaction of the medically significant component with the chemistry comprises applying across a pair of the first, second and third terminals of the instrument a second signal and assessing the reaction of the medically significant component with the chemistry in response to the second signal.
  37. 37. The method of claim 33 wherein applying across the first and second terminals of the instrument a first signal comprises applying across the first and second terminals of the instrument a second signal, determining a second response to the second signal, and determining if the assessment controller proceeds with the application of the first signal.
  38. 38. The method of claim 33, 34, 35 36 or 37 wherein applying the first signal comprises applying a first signal having an AC component.
  39. 39. The method of claim 33, 34, 35, 36 or 37 wherein applying the first signal comprises applying a first AC signal.
  40. 40. The method of claim 37 wherein applying a second signal comprises applying a second signal having an AC component.
  41. 41. The method of claim 40 wherein applying a second signal comprises applying an AC second signal.
  42. 42. An apparatus for determining the concentration of a medically significant component of a biological fluid comprising a cell for receiving a sample of the fluid, the cell supporting a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, the instrument including an assessment controller for applying across the first and second terminals of the instrument a first signal, for determining the identity of the sample in response of the cell to the first signal, and for producing an indication of the identity of the sample.
  43. 43. The apparatus of claim 42 wherein the assessment controller comprises an assessment controller for applying across the first and second terminals a signal having an AC component.
  44. 44. The apparatus of claim 43 wherein the assessment controller comprises an assessment controller for applying across the first and second terminals an AC signal.
  45. 45. The apparatus of claim 42 wherein the instrument further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument, the assessment controller applying across a pair of the first, second and third terminals of the instrument a second signal, determining a first correction value in response of the cell to the second signal, assessing the reaction of the medically significant component with the chemistry, and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  46. 46. The apparatus of claim 45 wherein the assessment controller for assessing the reaction of the medically significant component with the chemistry comprises an assessment controller for applying across a pair of the first, second and third terminals of the instrument a third signal, determining a third response to the third signal, the third response determining if the assessment controller proceeds with the application of at least one of the first and second signals.
  47. 47. The apparatus of claim 42 wherein the assessment controller further comprises a third terminal, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument, the assessment controller applying across a pair of the first, second and third terminals of the instrument a second signal, determining a second response to the second signal, the second response determining if the assessment controller proceeds with the application of the first signal.
  48. 48. A method for determining the concentration of a medically significant component of a biological fluid comprising providing a cell for receiving a sample of the fluid, providing on the cell a chemistry which reacts with the medically significant component and first and second terminals across which the reaction of the chemistry with the medically significant component can be assessed, providing an instrument having first and second terminals complementary to the first and second terminals, respectively, of the cell, placement of the first and second terminals of the cell in contact with the first and second terminals, respectively, of the instrument permitting the instrument to assess the reaction, providing in the instrument an assessment controller for applying across the first and second terminals of the instrument a first signal, determining the identity of the sample in response of the cell to the first signal, and producing an indication of the identity of the sample.
  49. 49. The method of claim 48 wherein the step of providing an instrument having first and second terminals comprises the step of providing an instrument having first, second and third terminals, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument, the assessment controller applying across a pair of the first, second and third terminals of the instrument a second signal, determining a first correction value in response of the cell to the second signal, assessing the reaction of the medically significant component with the chemistry, and combining the correction value with the result of the reaction assessment to produce an indication of the concentration of the medically significant component in the sample.
  50. 50. The method of claim 49 wherein the assessment controller applies across a pair of the first, second and third terminals of the instrument a third signal and determines a third response to the third signal, the third response determining if the assessment controller proceeds with the application of at least one of the first and second signals.
  51. 51. The method of claim 48 wherein the step of providing an instrument having first and second terminals comprises the step of providing an instrument having first, second and third terminals, placement of the first and second terminals of the cell in contact with the first and second terminals of the instrument placing one of the first and second terminals of the cell in contact with the third terminal of the instrument, the assessment controller applying across a pair of the first, second and third terminals of the instrument a second signal and determining a second response to the second signal, the second response determining if the assessment controller proceeds with the application of the first signal.
US10264890 1997-12-22 2002-10-04 Meter Abandoned US20040005716A9 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US99628097 true 1997-12-22 1997-12-22
US09530171 US6645368B1 (en) 1997-12-22 1998-12-21 Meter and method of using the meter for determining the concentration of a component of a fluid
EP01203816.2 2001-10-09
US10264890 US20040005716A9 (en) 1997-12-22 2002-10-04 Meter

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10264890 US20040005716A9 (en) 1997-12-22 2002-10-04 Meter
US10688343 US7407811B2 (en) 1997-12-22 2003-10-17 System and method for analyte measurement using AC excitation
US10688312 US7390667B2 (en) 1997-12-22 2003-10-17 System and method for analyte measurement using AC phase angle measurements
US10687668 US7494816B2 (en) 1997-12-22 2003-10-17 System and method for determining a temperature during analyte measurement
US11376858 US7338639B2 (en) 1997-12-22 2006-03-16 System and method for analyte measurement
US11970952 US7981363B2 (en) 1997-12-22 2008-01-08 System and method for analyte measurement
US12246885 US8071384B2 (en) 1997-12-22 2008-10-07 Control and calibration solutions and methods for their use
US13156921 US20110236963A1 (en) 1997-12-22 2011-06-09 System and method for analyte measurement
US13364365 US8691152B2 (en) 1997-12-22 2012-02-02 System and method for analyte measurement

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
US09530171 Division
US09530171 Division US6645368B1 (en) 1997-12-22 1998-12-21 Meter and method of using the meter for determining the concentration of a component of a fluid
US09530171 Division 1998-12-21
PCT/US1998/027203 Division WO1999032881A1 (en) 1997-12-22 1998-12-21 Meter

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10688343 Continuation-In-Part US7407811B2 (en) 1997-12-22 2003-10-17 System and method for analyte measurement using AC excitation
US10688312 Continuation-In-Part US7390667B2 (en) 1997-12-22 2003-10-17 System and method for analyte measurement using AC phase angle measurements
US10687668 Continuation-In-Part US7494816B2 (en) 1997-12-22 2003-10-17 System and method for determining a temperature during analyte measurement

Publications (2)

Publication Number Publication Date
US20030064525A1 true true US20030064525A1 (en) 2003-04-03
US20040005716A9 true US20040005716A9 (en) 2004-01-08

Family

ID=25542720

Family Applications (2)

Application Number Title Priority Date Filing Date
US09530171 Expired - Lifetime US6645368B1 (en) 1997-12-22 1998-12-21 Meter and method of using the meter for determining the concentration of a component of a fluid
US10264890 Abandoned US20040005716A9 (en) 1997-12-22 2002-10-04 Meter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09530171 Expired - Lifetime US6645368B1 (en) 1997-12-22 1998-12-21 Meter and method of using the meter for determining the concentration of a component of a fluid

Country Status (8)

Country Link
US (2) US6645368B1 (en)
EP (3) EP2085779B1 (en)
JP (1) JP3260739B2 (en)
CN (2) CN1183384C (en)
CA (1) CA2310021C (en)
DE (1) DE69840916D1 (en)
ES (1) ES2326145T3 (en)
WO (1) WO1999032881A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113896A2 (en) * 2003-06-20 2004-12-29 Roche Diagnostics Gmbh System and method for analysis of a biological fluid by the use electrical means
WO2005003748A1 (en) * 2003-06-20 2005-01-13 Roche Diagnostics Gmbh System and method for glucose and hematocrit measurement using ac phase angle measurements
US20050265094A1 (en) * 2004-05-30 2005-12-01 Agamatrix, Inc. Measuring device and methods for use therewith
WO2005114163A1 (en) * 2004-05-14 2005-12-01 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
US20050276133A1 (en) * 2004-05-30 2005-12-15 Agamatrix, Inc. Measuring device and methods for use therewith
US20060231423A1 (en) * 2005-04-15 2006-10-19 Agamatrix, Inc Analyte determination method and analyte meter
US20070264721A1 (en) * 2003-10-17 2007-11-15 Buck Harvey B System and method for analyte measurement using a nonlinear sample response
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US20100319436A1 (en) * 2009-06-23 2010-12-23 Bayer Healthcare Llc System and Apparatus for Determining Temperatures in a Fluid Analyte System
US20110168575A1 (en) * 2010-01-08 2011-07-14 Roche Diaagnostics Operations, Inc. Sample characterization based on ac measurement methods
US8026104B2 (en) 2006-10-24 2011-09-27 Bayer Healthcare Llc Transient decay amperometry
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US8092668B2 (en) 2004-06-18 2012-01-10 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
WO2013030369A1 (en) * 2011-09-02 2013-03-07 Lifescan Scotland Limited Hematocrit corrected glucose measurements using phase angles and impedance for electrochemical test strip
US8401873B2 (en) 2007-05-30 2013-03-19 Bayer Healthcare Llc Health data management device
US8404100B2 (en) 2005-09-30 2013-03-26 Bayer Healthcare Llc Gated voltammetry
US8425757B2 (en) 2005-07-20 2013-04-23 Bayer Healthcare Llc Gated amperometry
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US20150276671A1 (en) * 2012-07-20 2015-10-01 Apex Biotechnology Corp. Electrode strip and sensor strip and manufacture method thereof and system thereof
US9410917B2 (en) 2004-02-06 2016-08-09 Ascensia Diabetes Care Holdings Ag Method of using a biosensor
US9933385B2 (en) 2007-12-10 2018-04-03 Ascensia Diabetes Care Holdings Ag Method of using an electrochemical test sensor
US9976977B2 (en) * 2013-03-15 2018-05-22 Roche Diabetes Care, Inc. Methods of scaling data used to construct biosensor algorithms as well as devices, apparatuses and systems incorporating the same

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US7494816B2 (en) * 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
CA2310021C (en) * 1997-12-22 2005-02-15 Roche Diagnostics Corporation An apparatus and method for determining the concentration of a component in a fluid
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6475372B1 (en) * 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
JP3972063B2 (en) * 2001-01-17 2007-09-05 アークレイ株式会社 Quantitative analysis method and quantitative analysis apparatus using sensors
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
WO2002100460A3 (en) 2001-06-12 2003-05-08 Don Alden Electric lancet actuator
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
EP1404235A4 (en) 2001-06-12 2008-08-20 Pelikan Technologies Inc Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
CN100401045C (en) 2001-07-18 2008-07-09 爱科来株式会社 Implement and device for analysis
US6797150B2 (en) * 2001-10-10 2004-09-28 Lifescan, Inc. Determination of sample volume adequacy in biosensor devices
US7018843B2 (en) * 2001-11-07 2006-03-28 Roche Diagnostics Operations, Inc. Instrument
US6872298B2 (en) * 2001-11-20 2005-03-29 Lifescan, Inc. Determination of sample volume adequacy in biosensor devices
US6856125B2 (en) * 2001-12-12 2005-02-15 Lifescan, Inc. Biosensor apparatus and method with sample type and volume detection
KR20040077722A (en) * 2002-01-15 2004-09-06 아가매트릭스, 인코포레이티드 Method and apparatus for processing electrochemical signals
KR20040103928A (en) * 2002-02-10 2004-12-09 아가매트릭스, 인코포레이티드 Method and apparatus for assay of electrochemical properties
CN1639563A (en) * 2002-03-08 2005-07-13 松下电器产业株式会社 Substrate determining method
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US6743635B2 (en) * 2002-04-25 2004-06-01 Home Diagnostics, Inc. System and methods for blood glucose sensing
US8202439B2 (en) 2002-06-05 2012-06-19 Panasonic Corporation Diaphragm and device for measuring cellular potential using the same, manufacturing method of the diaphragm
DE50312044D1 (en) 2002-08-23 2009-12-03 Hoffmann La Roche Flow cell with a device for verifying the positioning and freedom of the bladder of a medical microsample
CA2437249A1 (en) * 2002-08-27 2004-02-27 Bayer Healthcare, Llc Methods of determining glucose concentration in whole blood samples
DE10244775A1 (en) 2002-09-26 2004-04-08 Roche Diagnostics Gmbh Capillary sensor analysis system
KR100485671B1 (en) * 2002-09-30 2005-04-27 주식회사 인포피아 A measuring instrument for biosensor
US20040108226A1 (en) * 2002-10-28 2004-06-10 Constantin Polychronakos Continuous glucose quantification device and method
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
EP1467206A1 (en) * 2003-04-08 2004-10-13 F.Hoffmann-La Roche Ag Biosensor system
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7488601B2 (en) * 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US7597793B2 (en) * 2003-06-20 2009-10-06 Roche Operations Ltd. System and method for analyte measurement employing maximum dosing time delay
WO2005022143B1 (en) 2003-08-21 2005-11-10 Agamatrix Inc Method and apparatus for assay of electrochemical properties
WO2005033659A3 (en) 2003-09-29 2007-01-18 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
WO2005040784A1 (en) * 2003-10-29 2005-05-06 Arkray, Inc. Specimen analysis method and specimen analysis device
JP4552423B2 (en) 2003-11-21 2010-09-29 パナソニック株式会社 Method of measuring extracellular potential measuring device and extracellular potential using the same
EP2579031B1 (en) 2003-12-04 2017-09-27 Panasonic Healthcare Holdings Co., Ltd. Biosensor for measuring blood component and hematocrit.
KR101049330B1 (en) 2003-12-04 2011-07-13 파나소닉 주식회사 How to measure the hematocrit, and the sensor and measuring device using it
WO2005065414A3 (en) 2003-12-31 2005-12-29 Pelikan Technologies Inc Method and apparatus for improving fluidic flow and sample capture
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
CA2557690A1 (en) * 2004-03-31 2005-10-20 George A. Mecklenburg Method and apparatus for implementing threshold based correction functions for biosensors
EP1742045B1 (en) * 2004-04-19 2016-11-02 Panasonic Healthcare Holdings Co., Ltd. Method for measuring blood components and biosensor and measuring instrument for use therein
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
CA2984221A1 (en) * 2004-06-18 2005-12-29 F. Hoffmann-La Roche Ag System and method for quality assurance of a biosensor test strip
US7556723B2 (en) 2004-06-18 2009-07-07 Roche Diagnostics Operations, Inc. Electrode design for biosensor
EP1774303A4 (en) * 2004-07-22 2009-05-06 Targetgen Inc Method and apparatus for electrochemical detection
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8192599B2 (en) 2005-05-25 2012-06-05 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8323464B2 (en) 2005-05-25 2012-12-04 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8016154B2 (en) 2005-05-25 2011-09-13 Lifescan, Inc. Sensor dispenser device and method of use
WO2007019395A1 (en) * 2005-08-05 2007-02-15 Bayer Healthcare Llc Method for distinguishing electrochemical sensors
EP1937832A4 (en) * 2005-09-13 2008-09-10 Home Diagnostics Inc Method of manufacturing a diagnostic test strip
US7749371B2 (en) 2005-09-30 2010-07-06 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
RU2499996C2 (en) * 2005-11-14 2013-11-27 Байер Хелткэр Ллк Analysing sensor reagent having cellulose polymers
EP1813937A1 (en) 2006-01-25 2007-08-01 Boehringer Mannheim Gmbh Electrochemical biosensor analysis system
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8529751B2 (en) 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US8398443B2 (en) * 2006-04-21 2013-03-19 Roche Diagnostics Operations, Inc. Biological testing system and connector therefor
US8287718B2 (en) 2006-07-05 2012-10-16 Panasonic Corporation Liquid sample measurement method and apparatus
US8177957B2 (en) * 2006-08-22 2012-05-15 Lawrence Livermore National Security, Llc Multiple frequency method for operating electrochemical sensors
US7751864B2 (en) * 2007-03-01 2010-07-06 Roche Diagnostics Operations, Inc. System and method for operating an electrochemical analyte sensor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US7768387B2 (en) * 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
JP4904219B2 (en) * 2007-07-24 2012-03-28 株式会社タニタ Liquid component measuring device
US7794658B2 (en) * 2007-07-25 2010-09-14 Lifescan, Inc. Open circuit delay devices, systems, and methods for analyte measurement
US8778168B2 (en) 2007-09-28 2014-07-15 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US8001825B2 (en) 2007-11-30 2011-08-23 Lifescan, Inc. Auto-calibrating metering system and method of use
JP5812603B2 (en) * 2007-12-10 2015-11-17 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC Gradient-based correction
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
US8431011B2 (en) * 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
CA2659142C (en) 2008-03-21 2017-10-03 Lifescan Scotland Limited Analyte testing method and system
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US8551320B2 (en) 2008-06-09 2013-10-08 Lifescan, Inc. System and method for measuring an analyte in a sample
CN102238900A (en) * 2008-10-03 2011-11-09 拜尔健康护理有限责任公司 System and method for predicting ambient temperature in a fluid analyte meter
JP5738770B2 (en) 2008-12-08 2015-06-24 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC Biosensor system with signal conditioning
RU2546862C2 (en) * 2008-12-08 2015-04-10 БАЙЕР ХЕЛТКЭА ЭлЭлСи Biosensor system and test sensors for determination of concentration of analysed substance (versions)
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
KR101529407B1 (en) 2008-12-23 2015-06-16 에프. 호프만-라 로슈 아게 Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US20120088989A1 (en) 2009-12-21 2012-04-12 Roche Diagnostic Operations, Inc. Management Method And System For Implementation, Execution, Data Collection, and Data Analysis of A Structured Collection Procedure Which Runs On A Collection Device
US20110145747A1 (en) 2008-12-23 2011-06-16 Roche Diagnostics Operations, Inc. Structured Tailoring
US20110178820A1 (en) 2008-12-23 2011-07-21 Roche Diagnostics Operations, Inc. Status Reporting Of A Structured Collection Procedure
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US20100198107A1 (en) 2009-01-30 2010-08-05 Roche Diagnostics Operations, Inc. Integrated blood glucose meter and lancing device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8608937B2 (en) 2009-03-30 2013-12-17 Roche Diagnostics Operations, Inc. Biosensor with predetermined dose response curve and method of manufacturing
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9218453B2 (en) * 2009-06-29 2015-12-22 Roche Diabetes Care, Inc. Blood glucose management and interface systems and methods
US20100331652A1 (en) 2009-06-29 2010-12-30 Roche Diagnostics Operations, Inc. Modular diabetes management systems
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
US8622231B2 (en) 2009-09-09 2014-01-07 Roche Diagnostics Operations, Inc. Storage containers for test elements
US20110092788A1 (en) * 2009-10-15 2011-04-21 Roche Diagnostics Operations, Inc. Systems And Methods For Providing Guidance In Administration Of A Medicine
US20110118578A1 (en) 2009-11-17 2011-05-19 Roche Diagnostics Operations, Inc. Hypoglycemic treatment methods and systems
US20110151571A1 (en) 2009-12-23 2011-06-23 Roche Diagnostics Operations, Inc. Memory apparatus for multiuse analyte test element systems, and kits, systems, combinations and methods relating to same
US20110186428A1 (en) 2010-01-29 2011-08-04 Roche Diagnostics Operations, Inc. Electrode arrangements for biosensors
US20110208435A1 (en) * 2010-02-25 2011-08-25 Lifescan Scotland Ltd. Capacitance detection in electrochemical assays
KR20130016311A (en) * 2010-03-22 2013-02-14 바이엘 헬쓰케어, 엘엘씨 Residual compensation for a biosensor
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
WO2011156152A1 (en) 2010-06-07 2011-12-15 Bayer Healthcare Llc Slope-based compensation including secondary output signals
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
EP2596115B1 (en) 2010-07-23 2016-03-16 Roche Diagnostics GmbH Zwitterion buffer containing compositions and uses in electroanalytical devices and methods
US8427817B2 (en) 2010-10-15 2013-04-23 Roche Diagnostics Operations, Inc. Handheld diabetes manager with touch screen display
US8648396B2 (en) 2010-10-18 2014-02-11 Industrial Technology Research Institute Microsystem for analyzing blood
CN102466652A (en) * 2010-11-19 2012-05-23 财团法人工业技术研究院 Blood analysis micro system
US20120143085A1 (en) 2010-12-02 2012-06-07 Matthew Carlyle Sauers Test element ejection mechanism for a meter
EP2656058A1 (en) * 2010-12-22 2013-10-30 Roche Diagnostics GmbH Systems and methods to compensate for sources of error during electrochemical testing
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
JP6082396B2 (en) 2011-09-21 2017-02-15 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC Bio-sensor with the error compensation
JP2015505251A (en) 2011-11-07 2015-02-19 アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. Analyte monitoring device and method
US9914126B2 (en) 2011-11-28 2018-03-13 Roche Diabetes Care, Inc. Storage container for biosensor test elements
US9903830B2 (en) * 2011-12-29 2018-02-27 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip based on sensed physical characteristic(s) of the sample containing the analyte
WO2013107757A1 (en) * 2012-01-18 2013-07-25 Roche Diagnostics Gmbh Amplifier circuitry for a combined ac/dc signal of an electrochemical sensing electrode
US20140068487A1 (en) 2012-09-05 2014-03-06 Roche Diagnostics Operations, Inc. Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
EP2972273A1 (en) 2013-03-15 2016-01-20 Roche Diagnostics GmbH Methods of using information from recovery pulses in electrochemical analyte measurements as well as devices, apparatuses and systems incorporating the same
CA2900883C (en) 2013-03-15 2017-10-24 F. Hoffmann-La Roche Ag Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same
CN105247357B (en) 2013-03-15 2017-12-12 豪夫迈·罗氏有限公司 Detection of high levels of antioxidants and methods for analyte concentration from fail-binding substance and its equipment, apparatus and system during the electrochemical measurement
US20140299483A1 (en) * 2013-04-05 2014-10-09 Lifescan Scotland Limited Analyte meter and method of operation
US9243276B2 (en) 2013-08-29 2016-01-26 Lifescan Scotland Limited Method and system to determine hematocrit-insensitive glucose values in a fluid sample
US9459231B2 (en) 2013-08-29 2016-10-04 Lifescan Scotland Limited Method and system to determine erroneous measurement signals during a test measurement sequence
GB2521481B (en) * 2013-12-23 2016-05-25 Lifescan Scotland Ltd Hand-held test meter with an operating range test strip simulation circuit block
WO2018080637A1 (en) * 2016-10-24 2018-05-03 Roche Diabetes Care, Inc. Methods of correcting for uncompensated resistances in the conductive elements of biosensors, as well as devices and systems

Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US98233A (en) * 1869-12-28 Improved signal for railways
US3770607A (en) * 1970-04-07 1973-11-06 Secretary Glucose determination apparatus
US3838033A (en) * 1971-09-09 1974-09-24 Hoffmann La Roche Enzyme electrode
US3902970A (en) * 1973-07-30 1975-09-02 Leeds & Northrup Co Flow-through amperometric measuring system and method
US3925183A (en) * 1972-06-16 1975-12-09 Energetics Science Gas detecting and quantitative measuring device
US3937615A (en) * 1974-12-17 1976-02-10 Leeds & Northrup Company Auto-ranging glucose measuring system
US3948745A (en) * 1973-06-11 1976-04-06 The United States Of America As Represented By The Department Of Health, Education And Welfare Enzyme electrode
US4005002A (en) * 1973-08-06 1977-01-25 Hoffmann-La Roche Inc. Apparatus for measuring substrate concentrations
US4040908A (en) * 1976-03-12 1977-08-09 Children's Hospital Medical Center Polarographic analysis of cholesterol and other macromolecular substances
US4086631A (en) * 1974-12-23 1978-04-25 Hycel, Inc. Hematocrit measurement in an automatic hematology analyzer
US4123701A (en) * 1976-07-01 1978-10-31 United States Surgical Corporation Disposable sample card having a well with electrodes for testing a liquid sample
US4224125A (en) * 1977-09-28 1980-09-23 Matsushita Electric Industrial Co., Ltd. Enzyme electrode
US4225410A (en) * 1978-12-04 1980-09-30 Technicon Instruments Corporation Integrated array of electrochemical sensors
US4230537A (en) * 1975-12-18 1980-10-28 Monsanto Company Discrete biochemical electrode system
US4260680A (en) * 1977-10-22 1981-04-07 Mitsubishi Chemical Industries, Ltd. Method and apparatus for the measurement of glucose content
US4263343A (en) * 1979-08-13 1981-04-21 Eastman Kodak Company Reference elements for ion-selective membrane electrodes
US4265250A (en) * 1979-07-23 1981-05-05 Battle Research And Development Associates Electrode
US4301412A (en) * 1979-10-29 1981-11-17 United States Surgical Corporation Liquid conductivity measuring system and sample cards therefor
US4303887A (en) * 1979-10-29 1981-12-01 United States Surgical Corporation Electrical liquid conductivity measuring system
US4366033A (en) * 1978-04-20 1982-12-28 Siemens Aktiengesellschaft Method for determining the concentration of sugar using an electrocatalytic sugar sensor
US4405511A (en) * 1981-03-21 1983-09-20 Chemische Fabrik Kreussler & Co. Gmbh Cleaning intensifier for use in dry-cleaning machines equipped with adsorption filters
US4407959A (en) * 1980-10-29 1983-10-04 Fuji Electric Co., Ltd. Blood sugar analyzing apparatus
US4413628A (en) * 1980-11-19 1983-11-08 Tamulis Walter G pH Monitor electrode electrolyte cartridge
US4420564A (en) * 1980-11-21 1983-12-13 Fuji Electric Company, Ltd. Blood sugar analyzer having fixed enzyme membrane sensor
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
US4477314A (en) * 1982-07-30 1984-10-16 Siemens Aktiengesellschaft Method for determining sugar concentration
US4477575A (en) * 1980-08-05 1984-10-16 Boehringer Mannheim Gmbh Process and composition for separating plasma or serum from whole blood
US4517291A (en) * 1983-08-15 1985-05-14 E. I. Du Pont De Nemours And Company Biological detection process using polymer-coated electrodes
US4652830A (en) * 1985-04-18 1987-03-24 Eg&G Ocean Products, Inc. Analyzer for comparative measurements of bulk conductivity
US4654197A (en) * 1983-10-18 1987-03-31 Aktiebolaget Leo Cuvette for sampling and analysis
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
US4682602A (en) * 1981-05-07 1987-07-28 Ottosensor Corporation Probe for medical application
US4703756A (en) * 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4711245A (en) * 1983-05-05 1987-12-08 Genetics International, Inc. Sensor for components of a liquid mixture
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
US4734184A (en) * 1985-08-29 1988-03-29 Diamond Sensor Systems, Inc. Self-activating hydratable solid-state electrode apparatus
US4750496A (en) * 1987-01-28 1988-06-14 Xienta, Inc. Method and apparatus for measuring blood glucose concentration
US4759828A (en) * 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4795542A (en) * 1986-04-24 1989-01-03 St. Jude Medical, Inc. Electrochemical concentration detector device
US4999632A (en) * 1989-12-15 1991-03-12 Boehringer Mannheim Corporation Analog to digital conversion with noise reduction
US5108564A (en) * 1988-03-15 1992-04-28 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5112455A (en) * 1990-07-20 1992-05-12 I Stat Corporation Method for analytically utilizing microfabricated sensors during wet-up
US5128015A (en) * 1988-03-15 1992-07-07 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5202261A (en) * 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
US5243516A (en) * 1989-12-15 1993-09-07 Boehringer Mannheim Corporation Biosensing instrument and method
US5269891A (en) * 1989-03-09 1993-12-14 Novo Nordisk A/S Method and apparatus for determination of a constituent in a fluid
US5288636A (en) * 1989-12-15 1994-02-22 Boehringer Mannheim Corporation Enzyme electrode system
US5312762A (en) * 1989-03-13 1994-05-17 Guiseppi Elie Anthony Method of measuring an analyte by measuring electrical resistance of a polymer film reacting with the analyte
US5332479A (en) * 1991-05-17 1994-07-26 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5343351A (en) * 1991-11-18 1994-08-30 Electro-Tech, Inc. Starter motor protection circuit with relay protection
US5352351A (en) * 1993-06-08 1994-10-04 Boehringer Mannheim Corporation Biosensing meter with fail/safe procedures to prevent erroneous indications
US5354447A (en) * 1991-12-12 1994-10-11 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5366609A (en) * 1993-06-08 1994-11-22 Boehringer Mannheim Corporation Biosensing meter with pluggable memory key
US5385846A (en) * 1993-06-03 1995-01-31 Boehringer Mannheim Corporation Biosensor and method for hematocrit determination
US5395504A (en) * 1993-02-04 1995-03-07 Asulab S.A. Electrochemical measuring system with multizone sensors
US5427912A (en) * 1993-08-27 1995-06-27 Boehringer Mannheim Corporation Electrochemical enzymatic complementation immunoassay
US5438271A (en) * 1993-06-08 1995-08-01 Boehringer Mannheim Corporation Biosensing meter which detects proper electrode engagement and distinguishes sample and check strips
US5437999A (en) * 1994-02-22 1995-08-01 Boehringer Mannheim Corporation Electrochemical sensor
US5469846A (en) * 1992-10-19 1995-11-28 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5508171A (en) * 1989-12-15 1996-04-16 Boehringer Mannheim Corporation Assay method with enzyme electrode system
US5508203A (en) * 1993-08-06 1996-04-16 Fuller; Milton E. Apparatus and method for radio frequency spectroscopy using spectral analysis
US5509410A (en) * 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
US5630986A (en) * 1995-01-13 1997-05-20 Bayer Corporation Dispensing instrument for fluid monitoring sensors
US5704354A (en) * 1994-06-23 1998-01-06 Siemens Aktiengesellschaft Electrocatalytic glucose sensor
US5723284A (en) * 1996-04-01 1998-03-03 Bayer Corporation Control solution and method for testing the performance of an electrochemical device for determining the concentration of an analyte in blood
US5792668A (en) * 1993-08-06 1998-08-11 Solid State Farms, Inc. Radio frequency spectral analysis for in-vitro or in-vivo environments
US5863400A (en) * 1994-04-14 1999-01-26 Usf Filtration & Separations Group Inc. Electrochemical cells
US6001239A (en) * 1998-09-30 1999-12-14 Mercury Diagnostics, Inc. Membrane based electrochemical test device and related methods
US6069011A (en) * 1997-12-10 2000-05-30 Umm Electronics, Inc. Method for determining the application of a sample fluid on an analyte strip using first and second derivatives
US20010053535A1 (en) * 2000-04-17 2001-12-20 Purdue Research Foundation Biosensor and related method
US20020033345A1 (en) * 1997-06-12 2002-03-21 Clinical Micro Sensors, Inc. Detection of analytes using reorganization energy
US20020175075A1 (en) * 2001-05-21 2002-11-28 Yingping Deng Electrochemical sensor
US6645368B1 (en) * 1997-12-22 2003-11-11 Roche Diagnostics Corporation Meter and method of using the meter for determining the concentration of a component of a fluid

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127448A (en) 1977-02-28 1978-11-28 Schick Karl G Amperometric-non-enzymatic method of determining sugars and other polyhydroxy compounds
US4214968A (en) 1978-04-05 1980-07-29 Eastman Kodak Company Ion-selective electrode
DE2823485C2 (en) 1978-05-30 1986-03-27 Albert Prof. Dr. 3550 Marburg De Huch
US4273134A (en) 1979-05-22 1981-06-16 Biochem International Inc. Fixation ring assembly and method of assembling a sensor head
US4816224B1 (en) 1980-08-05 1992-03-10 Boehringer Mannheim Gmbh
DE3047782A1 (en) 1980-12-18 1982-07-08 Draegerwerk Ag Circuit arrangement for the correction of the sensorausgangsgroesse
DE3228542A1 (en) 1982-07-30 1984-02-02 Siemens Ag A method for determining the concentration electrochemically metabolizable substances
US4820399A (en) 1984-08-31 1989-04-11 Shimadzu Corporation Enzyme electrodes
EP0230472B2 (en) 1985-06-21 2000-12-13 Matsushita Electric Industrial Co., Ltd. Biosensor and method of manufacturing same
US4938860A (en) 1985-06-28 1990-07-03 Miles Inc. Electrode for electrochemical sensors
US4686479A (en) 1985-07-22 1987-08-11 Young Chung C Apparatus and control kit for analyzing blood sample values including hematocrit
US4805624A (en) 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
EP0215669A3 (en) 1985-09-17 1989-08-30 Seiko Instruments Inc. Analytical device and method for analysis of biochemicals, microbes and cells
US4935106A (en) 1985-11-15 1990-06-19 Smithkline Diagnostics, Inc. Ion selective/enzymatic electrode medical analyzer device and method of use
GB8608700D0 (en) 1986-04-10 1986-05-14 Genetics Int Inc Measurement of electroactive species in solution
GB8612861D0 (en) 1986-05-27 1986-07-02 Cambridge Life Sciences Immobilised enzyme biosensors
JPH0419503B2 (en) 1986-06-27 1992-03-30 Terumo Corp
GB8618022D0 (en) 1986-07-23 1986-08-28 Unilever Plc Electrochemical measurements
JPS63111453A (en) 1986-10-29 1988-05-16 Omron Tateisi Electronics Co Enzyme electrode
US4897162A (en) 1986-11-14 1990-01-30 The Cleveland Clinic Foundation Pulse voltammetry
JPS63128252A (en) 1986-11-18 1988-05-31 Matsushita Electric Ind Co Ltd Biosensor
US4975647A (en) 1987-06-01 1990-12-04 Nova Biomedical Corporation Controlling machine operation with respect to consumable accessory units
US4940945A (en) 1987-11-02 1990-07-10 Biologix Inc. Interface circuit for use in a portable blood chemistry measuring apparatus
DE4011428A1 (en) * 1989-05-24 1990-11-29 Neubrandenburg Pharma Veb Bio-catalyst substrate concn. determn. - based on potentiometric and amperometric cell with bio-tensions
US4999582A (en) 1989-12-15 1991-03-12 Boehringer Mannheim Corp. Biosensor electrode excitation circuit
JPH03260739A (en) 1990-03-09 1991-11-20 Advantest Corp Sequence action type logic circuit
JPH0820412B2 (en) 1990-07-20 1996-03-04 松下電器産業株式会社 Quantitative analysis method using the disposable sensor, and a device
US5575403A (en) 1995-01-13 1996-11-19 Bayer Corporation Dispensing instrument for fluid monitoring sensors
US5620579A (en) * 1995-05-05 1997-04-15 Bayer Corporation Apparatus for reduction of bias in amperometric sensors

Patent Citations (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US98233A (en) * 1869-12-28 Improved signal for railways
US3770607A (en) * 1970-04-07 1973-11-06 Secretary Glucose determination apparatus
US3838033A (en) * 1971-09-09 1974-09-24 Hoffmann La Roche Enzyme electrode
US3925183A (en) * 1972-06-16 1975-12-09 Energetics Science Gas detecting and quantitative measuring device
US3948745A (en) * 1973-06-11 1976-04-06 The United States Of America As Represented By The Department Of Health, Education And Welfare Enzyme electrode
US3902970A (en) * 1973-07-30 1975-09-02 Leeds & Northrup Co Flow-through amperometric measuring system and method
US4005002A (en) * 1973-08-06 1977-01-25 Hoffmann-La Roche Inc. Apparatus for measuring substrate concentrations
US3937615A (en) * 1974-12-17 1976-02-10 Leeds & Northrup Company Auto-ranging glucose measuring system
US4086631A (en) * 1974-12-23 1978-04-25 Hycel, Inc. Hematocrit measurement in an automatic hematology analyzer
US4230537A (en) * 1975-12-18 1980-10-28 Monsanto Company Discrete biochemical electrode system
US4040908A (en) * 1976-03-12 1977-08-09 Children's Hospital Medical Center Polarographic analysis of cholesterol and other macromolecular substances
US4123701A (en) * 1976-07-01 1978-10-31 United States Surgical Corporation Disposable sample card having a well with electrodes for testing a liquid sample
US4224125A (en) * 1977-09-28 1980-09-23 Matsushita Electric Industrial Co., Ltd. Enzyme electrode
US4260680A (en) * 1977-10-22 1981-04-07 Mitsubishi Chemical Industries, Ltd. Method and apparatus for the measurement of glucose content
US4366033A (en) * 1978-04-20 1982-12-28 Siemens Aktiengesellschaft Method for determining the concentration of sugar using an electrocatalytic sugar sensor
US4225410A (en) * 1978-12-04 1980-09-30 Technicon Instruments Corporation Integrated array of electrochemical sensors
US4265250A (en) * 1979-07-23 1981-05-05 Battle Research And Development Associates Electrode
US4263343A (en) * 1979-08-13 1981-04-21 Eastman Kodak Company Reference elements for ion-selective membrane electrodes
US4301412A (en) * 1979-10-29 1981-11-17 United States Surgical Corporation Liquid conductivity measuring system and sample cards therefor
US4303887A (en) * 1979-10-29 1981-12-01 United States Surgical Corporation Electrical liquid conductivity measuring system
US4477575A (en) * 1980-08-05 1984-10-16 Boehringer Mannheim Gmbh Process and composition for separating plasma or serum from whole blood
US4477575B1 (en) * 1980-08-05 1992-04-21 Boehringer Mannheim Gmbh
US4407959A (en) * 1980-10-29 1983-10-04 Fuji Electric Co., Ltd. Blood sugar analyzing apparatus
US4413628A (en) * 1980-11-19 1983-11-08 Tamulis Walter G pH Monitor electrode electrolyte cartridge
US4420564A (en) * 1980-11-21 1983-12-13 Fuji Electric Company, Ltd. Blood sugar analyzer having fixed enzyme membrane sensor
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4405511A (en) * 1981-03-21 1983-09-20 Chemische Fabrik Kreussler & Co. Gmbh Cleaning intensifier for use in dry-cleaning machines equipped with adsorption filters
US4682602A (en) * 1981-05-07 1987-07-28 Ottosensor Corporation Probe for medical application
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4477314A (en) * 1982-07-30 1984-10-16 Siemens Aktiengesellschaft Method for determining sugar concentration
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
US4711245A (en) * 1983-05-05 1987-12-08 Genetics International, Inc. Sensor for components of a liquid mixture
US5509410A (en) * 1983-06-06 1996-04-23 Medisense, Inc. Strip electrode including screen printing of a single layer
US4517291A (en) * 1983-08-15 1985-05-14 E. I. Du Pont De Nemours And Company Biological detection process using polymer-coated electrodes
US4654197A (en) * 1983-10-18 1987-03-31 Aktiebolaget Leo Cuvette for sampling and analysis
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
US4652830A (en) * 1985-04-18 1987-03-24 Eg&G Ocean Products, Inc. Analyzer for comparative measurements of bulk conductivity
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4734184A (en) * 1985-08-29 1988-03-29 Diamond Sensor Systems, Inc. Self-activating hydratable solid-state electrode apparatus
US4795542A (en) * 1986-04-24 1989-01-03 St. Jude Medical, Inc. Electrochemical concentration detector device
US4703756A (en) * 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4750496A (en) * 1987-01-28 1988-06-14 Xienta, Inc. Method and apparatus for measuring blood glucose concentration
US4759828A (en) * 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US5128015A (en) * 1988-03-15 1992-07-07 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5108564A (en) * 1988-03-15 1992-04-28 Tall Oak Ventures Method and apparatus for amperometric diagnostic analysis
US5269891A (en) * 1989-03-09 1993-12-14 Novo Nordisk A/S Method and apparatus for determination of a constituent in a fluid
US5312762A (en) * 1989-03-13 1994-05-17 Guiseppi Elie Anthony Method of measuring an analyte by measuring electrical resistance of a polymer film reacting with the analyte
US4999632A (en) * 1989-12-15 1991-03-12 Boehringer Mannheim Corporation Analog to digital conversion with noise reduction
US5243516A (en) * 1989-12-15 1993-09-07 Boehringer Mannheim Corporation Biosensing instrument and method
US5288636A (en) * 1989-12-15 1994-02-22 Boehringer Mannheim Corporation Enzyme electrode system
US5508171A (en) * 1989-12-15 1996-04-16 Boehringer Mannheim Corporation Assay method with enzyme electrode system
US5202261A (en) * 1990-07-19 1993-04-13 Miles Inc. Conductive sensors and their use in diagnostic assays
US5112455A (en) * 1990-07-20 1992-05-12 I Stat Corporation Method for analytically utilizing microfabricated sensors during wet-up
US5332479A (en) * 1991-05-17 1994-07-26 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5343351A (en) * 1991-11-18 1994-08-30 Electro-Tech, Inc. Starter motor protection circuit with relay protection
US5354447A (en) * 1991-12-12 1994-10-11 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5469846A (en) * 1992-10-19 1995-11-28 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
US5395504A (en) * 1993-02-04 1995-03-07 Asulab S.A. Electrochemical measuring system with multizone sensors
US5385846A (en) * 1993-06-03 1995-01-31 Boehringer Mannheim Corporation Biosensor and method for hematocrit determination
US5366609A (en) * 1993-06-08 1994-11-22 Boehringer Mannheim Corporation Biosensing meter with pluggable memory key
US5438271A (en) * 1993-06-08 1995-08-01 Boehringer Mannheim Corporation Biosensing meter which detects proper electrode engagement and distinguishes sample and check strips
US5352351A (en) * 1993-06-08 1994-10-04 Boehringer Mannheim Corporation Biosensing meter with fail/safe procedures to prevent erroneous indications
US5508203A (en) * 1993-08-06 1996-04-16 Fuller; Milton E. Apparatus and method for radio frequency spectroscopy using spectral analysis
US5792668A (en) * 1993-08-06 1998-08-11 Solid State Farms, Inc. Radio frequency spectral analysis for in-vitro or in-vivo environments
US5427912A (en) * 1993-08-27 1995-06-27 Boehringer Mannheim Corporation Electrochemical enzymatic complementation immunoassay
US5437999A (en) * 1994-02-22 1995-08-01 Boehringer Mannheim Corporation Electrochemical sensor
US5863400A (en) * 1994-04-14 1999-01-26 Usf Filtration & Separations Group Inc. Electrochemical cells
US5704354A (en) * 1994-06-23 1998-01-06 Siemens Aktiengesellschaft Electrocatalytic glucose sensor
US5630986A (en) * 1995-01-13 1997-05-20 Bayer Corporation Dispensing instrument for fluid monitoring sensors
US5723284A (en) * 1996-04-01 1998-03-03 Bayer Corporation Control solution and method for testing the performance of an electrochemical device for determining the concentration of an analyte in blood
US20020033345A1 (en) * 1997-06-12 2002-03-21 Clinical Micro Sensors, Inc. Detection of analytes using reorganization energy
US6069011A (en) * 1997-12-10 2000-05-30 Umm Electronics, Inc. Method for determining the application of a sample fluid on an analyte strip using first and second derivatives
US6645368B1 (en) * 1997-12-22 2003-11-11 Roche Diagnostics Corporation Meter and method of using the meter for determining the concentration of a component of a fluid
US6001239A (en) * 1998-09-30 1999-12-14 Mercury Diagnostics, Inc. Membrane based electrochemical test device and related methods
US20010053535A1 (en) * 2000-04-17 2001-12-20 Purdue Research Foundation Biosensor and related method
US20020175075A1 (en) * 2001-05-21 2002-11-28 Yingping Deng Electrochemical sensor

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US8507289B1 (en) 2003-06-20 2013-08-13 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
WO2004113896A3 (en) * 2003-06-20 2005-02-17 Roche Diagnostics Gmbh System and method for analysis of a biological fluid by the use electrical means
US8586373B2 (en) 2003-06-20 2013-11-19 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
WO2004113896A2 (en) * 2003-06-20 2004-12-29 Roche Diagnostics Gmbh System and method for analysis of a biological fluid by the use electrical means
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
WO2005003748A1 (en) * 2003-06-20 2005-01-13 Roche Diagnostics Gmbh System and method for glucose and hematocrit measurement using ac phase angle measurements
US8293538B2 (en) 2003-06-20 2012-10-23 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US8083993B2 (en) 2003-06-20 2011-12-27 Riche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US20070264721A1 (en) * 2003-10-17 2007-11-15 Buck Harvey B System and method for analyte measurement using a nonlinear sample response
US10067082B2 (en) 2004-02-06 2018-09-04 Ascensia Diabetes Care Holdings Ag Biosensor for determining an analyte concentration
US9410917B2 (en) 2004-02-06 2016-08-09 Ascensia Diabetes Care Holdings Ag Method of using a biosensor
US7972861B2 (en) 2004-05-14 2011-07-05 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
WO2005114163A1 (en) * 2004-05-14 2005-12-01 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
US20070231914A1 (en) * 2004-05-14 2007-10-04 Yingping Deng Methods for Performing Hematocrit Adjustment in Glucose Assays and Devices for Same
US7964146B2 (en) 2004-05-30 2011-06-21 Agamatrix, Inc. Measuring device and methods for use therewith
US8591815B2 (en) 2004-05-30 2013-11-26 Agamatrix, Inc. Measuring device and methods for use therewith
US20110215004A1 (en) * 2004-05-30 2011-09-08 Agamatrix, Inc. Measuring device and methods for use therewith
US8852510B2 (en) 2004-05-30 2014-10-07 Agamatrix, Inc. Measuring device and methods for use therewith
US9097651B2 (en) 2004-05-30 2015-08-04 Agamatrix, Inc. Measuring device and methods for use therewith
US20050276133A1 (en) * 2004-05-30 2005-12-15 Agamatrix, Inc. Measuring device and methods for use therewith
US20050265094A1 (en) * 2004-05-30 2005-12-01 Agamatrix, Inc. Measuring device and methods for use therewith
US9709519B2 (en) 2004-05-30 2017-07-18 Agamatrix, Inc. Measuring device and methods for use therewith
US9267910B2 (en) 2004-05-30 2016-02-23 Agamatrix, Inc. Measuring device and methods for use therewith
US8092668B2 (en) 2004-06-18 2012-01-10 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
US20060231423A1 (en) * 2005-04-15 2006-10-19 Agamatrix, Inc Analyte determination method and analyte meter
US9857324B2 (en) 2005-04-15 2018-01-02 Agamatrix, Inc. Analyte determination method and analyte meter
US8361307B2 (en) 2005-04-15 2013-01-29 Agamatrix, Inc. Analyte determination method and analyte meter
US8329025B2 (en) 2005-04-15 2012-12-11 Agamatrix, Inc. Analyte determination method and analyte meter
US8758594B2 (en) 2005-04-15 2014-06-24 Agamatrix, Inc. Analyte determination method and analyte meter
US7964089B2 (en) 2005-04-15 2011-06-21 Agamatrix, Inc. Analyte determination method and analyte meter
US9234862B2 (en) 2005-04-15 2016-01-12 Agamatrix, Inc. Analyte determination method and analyte meter
US8877035B2 (en) 2005-07-20 2014-11-04 Bayer Healthcare Llc Gated amperometry methods
US8425757B2 (en) 2005-07-20 2013-04-23 Bayer Healthcare Llc Gated amperometry
US9835582B2 (en) 2005-09-30 2017-12-05 Ascensia Diabetes Care Holdings Ag Devices using gated voltammetry methods
US8647489B2 (en) 2005-09-30 2014-02-11 Bayer Healthcare Llc Gated voltammetry devices
US8404100B2 (en) 2005-09-30 2013-03-26 Bayer Healthcare Llc Gated voltammetry
US9110013B2 (en) 2005-09-30 2015-08-18 Bayer Healthcare Llc Gated voltammetry methods
US9005527B2 (en) 2006-10-24 2015-04-14 Bayer Healthcare Llc Transient decay amperometry biosensors
US8470604B2 (en) 2006-10-24 2013-06-25 Bayer Healthcare Llc Transient decay amperometry
US8026104B2 (en) 2006-10-24 2011-09-27 Bayer Healthcare Llc Transient decay amperometry
WO2008138553A1 (en) * 2007-05-09 2008-11-20 Roche Diagnostics Gmbh System and method for analyte measurement using a nonlinear sample response
US9189598B2 (en) 2007-05-30 2015-11-17 Bayer Healthcare Llc Fluid analyte meter
US8401873B2 (en) 2007-05-30 2013-03-19 Bayer Healthcare Llc Health data management device
US9933385B2 (en) 2007-12-10 2018-04-03 Ascensia Diabetes Care Holdings Ag Method of using an electrochemical test sensor
US20100319436A1 (en) * 2009-06-23 2010-12-23 Bayer Healthcare Llc System and Apparatus for Determining Temperatures in a Fluid Analyte System
US8617381B2 (en) 2009-06-23 2013-12-31 Bayer Healthcare Llc System and apparatus for determining temperatures in a fluid analyte system
US9664644B2 (en) 2009-06-23 2017-05-30 Ascensia Diabetes Care Holdings Ag System and apparatus for determining temperatures in a fluid analyte system
US9097650B2 (en) 2009-06-23 2015-08-04 Bayer Healthcare Llc System and apparatus for determining temperatures in a fluid analyte system
US20110168575A1 (en) * 2010-01-08 2011-07-14 Roche Diaagnostics Operations, Inc. Sample characterization based on ac measurement methods
US9322800B2 (en) 2011-09-02 2016-04-26 Lifescan Scotland Limited Hematocrit corrected glucose measurements using phase angles and impedance for electrochemical test strip
WO2013030369A1 (en) * 2011-09-02 2013-03-07 Lifescan Scotland Limited Hematocrit corrected glucose measurements using phase angles and impedance for electrochemical test strip
US20150276671A1 (en) * 2012-07-20 2015-10-01 Apex Biotechnology Corp. Electrode strip and sensor strip and manufacture method thereof and system thereof
US9880128B2 (en) * 2012-07-20 2018-01-30 Apex Biotechnology Corp. Electrode strip and sensor strip and manufacture method thereof and system thereof
US9976977B2 (en) * 2013-03-15 2018-05-22 Roche Diabetes Care, Inc. Methods of scaling data used to construct biosensor algorithms as well as devices, apparatuses and systems incorporating the same

Also Published As

Publication number Publication date Type
EP1042667A1 (en) 2000-10-11 application
US6645368B1 (en) 2003-11-11 grant
EP1042667A4 (en) 2001-05-09 application
EP2085778B1 (en) 2017-11-29 grant
ES2326145T3 (en) 2009-10-01 grant
CN1183384C (en) 2005-01-05 grant
CN1303478A (en) 2001-07-11 application
WO1999032881A1 (en) 1999-07-01 application
CN1598564A (en) 2005-03-23 application
JP2001527215A (en) 2001-12-25 application
DE69840916D1 (en) 2009-07-30 grant
CA2310021C (en) 2005-02-15 grant
EP2085779A1 (en) 2009-08-05 application
JP3260739B2 (en) 2002-02-25 grant
EP2085778A1 (en) 2009-08-05 application
US20040005716A9 (en) 2004-01-08 application
EP1042667B1 (en) 2009-06-17 grant
CA2310021A1 (en) 1999-07-01 application
EP2085779B1 (en) 2017-11-01 grant
CN1598564B (en) 2010-04-21 grant

Similar Documents

Publication Publication Date Title
US3707455A (en) Measuring system
Harrison et al. Characterization of perfluorosulfonic acid polymer coated enzyme electrodes and a miniaturized integrated potentiostat for glucose analysis in whole blood
Cosofret et al. Microfabricated sensor arrays sensitive to pH and K+ for ionic distribution measurements in the beating heart
US5672256A (en) Multi-electrode biosensor and system and method for manufacturing same
US6193873B1 (en) Sample detection to initiate timing of an electrochemical assay
US20030042150A1 (en) Electrochemical biosensor test strip with recognition electrode and readout meter using this test strip
US20080173552A1 (en) Gated Amperometry
US20050023152A1 (en) Devices and methods relating to electrochemical biosensors
EP1839571A1 (en) Methods for analyzing a sample in the presence of interferents
US5736029A (en) Amperometric dual-electrode sensors
US4935105A (en) Methods of operating enzyme electrode sensors
US20030178322A1 (en) Method and apparatus for processing electrochemical signals
US3933593A (en) Rate sensing batch analysis method
US7199594B2 (en) Biosensor apparatus and method with sample type and volume detection
US5405511A (en) Biosensing meter with ambient temperature estimation method and system
US6251260B1 (en) Potentiometric sensors for analytic determination
US5352351A (en) Biosensing meter with fail/safe procedures to prevent erroneous indications
US20060108236A1 (en) Biosensor system
US20080179197A1 (en) Gated Voltammetry
US20090177406A1 (en) Slope-Based Compensation
US20110168575A1 (en) Sample characterization based on ac measurement methods
US5112455A (en) Method for analytically utilizing microfabricated sensors during wet-up
EP1394545A1 (en) Method of determining a haematocrit corrected glucose concentration in whole blood samples wherein the haematocrit concentration is measured by impedance spectroscopy
GB2204408A (en) Biosensor device
US20110139634A1 (en) System and method for measuring analyte concentration with interferant correction

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCHE DIAGNOSTICS CORPORATION, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEATY, TERRY A.;KUHN, LANCE S.;SVETNIK, VLADIMIR;AND OTHERS;REEL/FRAME:013704/0033

Effective date: 20030106

AS Assignment

Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS CORPORATION;REEL/FRAME:015215/0061

Effective date: 20040101

Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC.,INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS CORPORATION;REEL/FRAME:015215/0061

Effective date: 20040101

AS Assignment

Owner name: ROCHE DIABETES CARE, INC., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS OPERATIONS, INC.;REEL/FRAME:036008/0670

Effective date: 20150302